Genmab A/S (GMAB) Stock Forecast & Price Target
GMAB$57.29+12.62 +28.25%
$35.23B
Market Cap
40.62
P/E
48.55
Forward P/E
37
Score
Genmab A/S (GMAB) Stock Forecast & Price Target
GMAB price $57.29 +12.62 +28.25%
- Ticker
- GMAB
- Price
- $57.29
- Change
- +12.62 +28.25%
- Market cap ?
- $35.23B
- P/E ?
- 40.62
- Forward P/E ?
- 48.55
- Dividend yield ?
- 0.00%
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 37
- Value
- 29
- Quality
- 63
- Growth
- 20
Stocklytics score rationale: value 29, quality 63, growth 20.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1816122000 | 2365436000 | 3025137000 | 5366000000 | 10111000000 | 8417000000 | 14505000000 | 16474000000 | 21526000000 | 3722933872 |
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and…
Fair value
GMAB fair value $81.67. Price $57.29. Price is 30% below fair value.
Below fair value, but more expensive than usual. A smaller discount than on more than 99% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Average free cash flow, last three years 5.25B. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 614.90M. Net debt 3.71B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-05 | — | 0.37 | — | 1.20B |
| 2026-08-06 | 0.54 | 0.37 | 1.16B | 1.12B |
| 2026-05-07 | 0.09 | 0.15 | 896.00M | 905.77M |
| 2026-02-17 | 0.05 | 0.46 | 1.06B | 1.07B |
| 2025-11-06 | 0.65 | 0.48 | 1.02B | 1.01B |
| 2025-08-07 | 0.54 | 0.39 | 924.81M | 952.56M |
| 2025-05-08 | 0.31 | 0.23 | 725.99M | 755.47M |
| 2025-02-12 | 0.57 | 0.36 | 895.80M | 894.71M |
| 2024-11-06 | 0.29 | 0.35 | 815.16M | 809.62M |
| 2024-08-08 | 0.22 | 0.29 | 789.59M | 732.47M |
| 2024-05-02 | 0.16 | 0.16 | 598.08M | 572.03M |
| 2024-02-14 | 0.36 | 0.34 | 675.34M | 671.21M |
| 2023-11-07 | 0.47 | 3.14 | 669.38M | 642.86M |
| 2023-08-03 | 0.30 | 2.18 | 613.29M | 601.13M |
| 2023-05-10 | 0.05 | 0.65 | 416.08M | 404.26M |
| 2023-02-22 | 0.12 | 3.15 | 754.97M | 681.42M |
| 2022-11-09 | 0.53 | 1.65 | 535.64M | 473.49M |
| 2022-08-10 | 0.41 | 1.55 | 443.98M | 412.04M |
| 2022-05-11 | 0.11 | 0.91 | 315.14M | 300.49M |
| 2022-02-16 | 0.17 | 5.30 | 399.16M | 389.00M |
| 2021-11-10 | 0.21 | 0.11 | 360.41M | 270.35M |
| 2021-08-11 | 0.08 | 0.08 | 314.36M | 353.27M |
| 2021-05-05 | 0.27 | 0.23 | 249.78M | 214.32M |
| 2021-02-23 | 0.14 | 1.28 | 335.62M | 563.55M |
| 2020-11-04 | 0.13 | 0.99 | 271.70M | 459.63M |
| 2020-08-12 | 0.76 | 0.88 | 822.37M | 231.81M |
| 2020-05-06 | 0.06 | 0.06 | 129.82M | 763.51M |
| 2020-02-19 | 0.34 | 0.36 | 449.49M | 430.54M |
| 2019-11-06 | 1.26 | 0.08 | 152.42M | 195.69M |
| 2019-08-20 | 0.20 | 0.27 | 117.59M | 144.85M |
| 2019-03-31 | 0.02 | — | 88.87M | — |
| 2018-12-31 | 0.22 | — | 198.32M | — |
| 2018-09-30 | 0.05 | — | 93.53M | — |
| 2018-06-30 | 0.07 | — | 79.34M | — |
| 2018-03-31 | 0.05 | — | 112.55M | — |
| 2017-12-31 | 0.20 | — | 160.31M | — |
| 2017-09-30 | -0.00 | — | 51.15M | — |
| 2017-06-30 | 0.08 | — | 118.46M | — |
| 2017-03-31 | 0.00 | — | 36.09M | — |
| 2016-12-31 | 0.19 | — | 130.83M | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| No data yet. | |||||
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 307, holders +26 vs prior quarter. Ownership 16.70%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| PARADIGM BIOCAPITAL ADVISORS LP | 13.13M | 5.17M | +64.83% | 360.77M |
| ORBIS ALLAN GRAY LTD | 11.37M | -1.56M | -12.05% | 312.28M |
| ALLIANCEBERNSTEIN L.P. | 8.64M | -912.27K | -9.55% | 231.94M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 6.87M | 4.40M | +178.84% | 188.58M |
| DEEP TRACK CAPITAL, LP | 5.65M | 1.99M | +54.23% | 155.21M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 4.98M | 0 | 0.00% | 136.67M |
| BLACKROCK, INC. | 4.67M | 134.69K | +2.97% | 128.32M |
| SOFINNOVA INVESTMENTS, INC. | 4.05M | 3.29M | +437.74% | 111.12M |
| RENAISSANCE TECHNOLOGIES LLC | 3.52M | -896.70K | -20.31% | 96.64M |
| TWO SIGMA INVESTMENTS, LP | 3.51M | 1.17M | +49.90% | 96.33M |
| HARDING LOEVNER LP | 3.09M | -145.28K | -4.50% | 86.90M |
| DEEP TRACK CAPITAL, LP | 3.00M | -663.25K | -18.11% | 82.41M |
| FIRST TRUST ADVISORS LP | 2.76M | 295.18K | +11.99% | 75.72M |
| CITADEL ADVISORS LLC | 2.48M | 2.30M | +1335.36% | 68.02M |
| QUBE RESEARCH & TECHNOLOGIES LTD | 1.69M | 1.01M | +149.40% | 46.40M |
| MORGAN STANLEY | 1.63M | -554.54K | -25.38% | 44.78M |
| FEDERATED HERMES, INC. | 1.45M | 197.79K | +15.80% | 39.81M |
| GOLDMAN SACHS GROUP INC | 1.28M | 347.97K | +37.37% | 35.14M |
| FRANKLIN TEMPLETON INC | 1.20M | 9.78K | +0.82% | 33.04M |
| PICTET ASSET MANAGEMENT HOLDING SA | 1.07M | -11.54K | -1.07% | 29.28M |
| UBS GROUP AG | 961.05K | 662.92K | +222.36% | 26.40M |
| PERPETUAL LTD | 919.05K | 160.54K | +21.17% | 25.25M |
| NORTHERN TRUST CORP | 916.60K | -33.93K | -3.57% | 25.18M |
| MILLENNIUM MANAGEMENT LLC | 910.60K | 118.31K | +14.93% | 25.01M |
| RUSSELL INVESTMENTS GROUP, LTD. | 883.43K | 86.36K | +10.83% | 24.27M |
Forecast
Consensus Buy from 12 analysts. Average price target $44.20, -22.8% versus the current price. Low $38.00. High $58.00.
Insights · Dividends · Forecast · Financials · Learn